Review: taking Lamisil and Wellbutrin together


Summary

Drug interactions are reported among people who take Lamisil and Wellbutrin together. This review analyzes the effectiveness and drug interactions between Lamisil and Wellbutrin. It is created by eHealthMe based on reports of 198 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Lamisil

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in nail tinea. (latest outcomes from Lamisil 11,081 users)

Wellbutrin

Wellbutrin has active ingredients of bupropion hydrochloride. It is often used in depression. (latest outcomes from Wellbutrin 69,048 users)

On Sep, 16, 2016

198 people who take Lamisil, Wellbutrin are studied.


Number of reports submitted per year:

Lamisil and Wellbutrin drug interactions.

Drug effectiveness over time:

Lamisil:
  • < 1 month: 33.0% - (2 of 6 people)
  • 1 - 6 months: 33.0% - (1 of 3 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Wellbutrin:
  • < 1 month: 75.0% - (3 of 4 people)
  • 1 - 6 months: 0.0% - (0 of 4 people)
  • 6 - 12 months: 66.0% - (2 of 3 people)
  • 1 - 2 years: 50.0% - (1 of 2 people)
  • 2 - 5 years: 75.0% - (3 of 4 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Lamisil:
  • female: 40.0% - (2 of 5 people)
  • male: 50.0% - (4 of 8 people)
Wellbutrin:
  • female: 55.0% - (5 of 9 people)
  • male: 44.0% - (4 of 9 people)

Drug effectiveness by age:

Lamisil:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 66.0% - (2 of 3 people)
  • 40-49: 25.0% - (1 of 4 people)
  • 50-59: 25.0% - (1 of 4 people)
  • 60+: 100.0% - (2 of 2 people)
Wellbutrin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 100.0% - (1 of 1 people)
  • 20-29: 100.0% - (1 of 1 people)
  • 30-39: 50.0% - (2 of 4 people)
  • 40-49: 20.0% - (1 of 5 people)
  • 50-59: 60.0% - (3 of 5 people)
  • 60+: 50.0% - (1 of 2 people)

Most common drug interactions over time *:

< 1 month:
  • rash
  • blood potassium decreased
  • cold weather and itchy skin
  • convulsion
  • dyspnoea
  • hallucinations
  • itching
  • abdominal pain upper
  • alanine aminotransferase increased
  • anorexia
1 - 6 months:
  • feeling abnormal
  • nausea
  • premature ejaculation
  • weight decreased
  • acid reflux
  • acute hepatic failure
  • ageusia
  • anxiety
  • depressed mood
  • diarrhoea
1 - 2 years:
  • rash
2 - 5 years:
  • constipation aggravated
  • fatigue - chronic
  • sleep disorder due to general medical condition, insomnia type
  • stress
5 - 10 years:
  • acid reflux
not specified:
  • anxiety
  • diabetes mellitus
  • depression
  • fatigue
  • gastrooesophageal reflux disease
  • hypertension
  • neuropathy peripheral
  • fall
  • pain
  • type 2 diabetes mellitus

Most common drug interactions by gender *:

female:
  • anxiety
  • diabetes mellitus
  • depression
  • fatigue
  • hypertension
  • neuropathy peripheral
  • panic attack
  • type 2 diabetes mellitus
  • gastrooesophageal reflux disease
  • diabetic neuropathy
male:
  • dizziness
  • fall
  • nasopharyngitis
  • upper respiratory tract infection
  • weight increased
  • pyrexia
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • cognitive disorder
  • cough

Most common drug interactions by age *:

10-19:
  • confusion
  • dizziness (excl vertigo)
  • fall
  • grand mal convulsion
  • laceration
  • loss of consciousness
  • pallor
  • post-ictal state
  • sweating increased
  • vision blurred
20-29:
  • anxiety
  • depression
  • drug withdrawal syndrome
  • erythema
  • irritability
  • obsessive-compulsive disorder
  • panic reaction
  • pruritus
  • rash
  • emotional distress
30-39:
  • type 2 diabetes mellitus
  • diabetes mellitus
  • post-traumatic stress disorder
  • hypertension
  • angina pectoris
  • cataract
  • coronary artery disease
  • dehydration
  • diabetic eye disease
  • diabetic neuropathy
40-49:
  • diabetes mellitus
  • gastrooesophageal reflux disease
  • fatigue
  • major depression
  • contusion
  • hepatic enzyme increased
  • asthma
  • bronchitis
  • bronchospasm
  • bursitis
50-59:
  • fall
  • dizziness
  • anxiety
  • nausea
  • urinary tract infection
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • lung adenocarcinoma metastatic
  • back pain
  • paraesthesia
60+:
  • upper respiratory tract infection
  • vertigo
  • weight increased
  • fatigue
  • nausea
  • overdose
  • pyrexia
  • thrombosis
  • adverse drug reaction
  • anaemia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Lamisil and Wellbutrin?

Can you answer these questions?

More questions for: Lamisil, Wellbutrin

You may be interested in these reviews

More reviews for: Lamisil, Wellbutrin

On eHealthMe, Lamisil (terbinafine hydrochloride) is often used to treat nail tinea. Wellbutrin (bupropion hydrochloride) is often used to treat depression. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.